Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-05
2008-10-14
Desai, Rita J (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S217080, C540S602000
Reexamination Certificate
active
07435833
ABSTRACT:
A compound of formula (I):or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Methods of inhibiting 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. Methods of treating non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
REFERENCES:
patent: 4324791 (1982-04-01), Welstead, Jr.
patent: 6784167 (2004-08-01), Wood et al.
patent: 1 180 513 (2002-02-01), None
patent: 03/059905 (2003-07-01), None
patent: 2004/089470 (2004-10-01), None
patent: 2005/108361 (2005-11-01), None
patent: 2006/104280 (2006-10-01), None
Anstead, G.M., “Steroids, Retinoids, and Wound Healing”,Adv. Wound Care, 11:277-285 (1998).
Armaly, M.F., “Dexamethasone Ocular Hypertension and Eosinopenia, and Glucose Tolerance Test”,Arch. Ophthalmol., 78:193-197 (1967).
Baxter, J.D., “Glucocorticoid Hormone Action”,Pharmac. Ther., 2:605-659 (1976).
Beer, H-D., et al., “Glucocorticoid-Regulated Gene Expression during Cutaneous Wound Repair”,Vitamins&Hormones, 59:217-239 (2000).
Belanoff, J.K., et al., “Corticosteroids and cognition”,J. of Psych. Res., 35:127-145 (2001).
Bertagna, X., et al., “Cushing's Disease,Cushing's Dis. In: Melmed S., Ed. The Pituitary”, 2ndEd(Chapt. 13):592-612 (2002).
Billaudel, B., et al., “Direct Effect of Corticostrone upon Insuline Secretion Studied by Three Different Techniques”,Horm. Metabl. Res., 11:555-560 (1979).
Bland, R., et al., “Characterization of 11β-hydroxysteroid dehydrongenase activity and corticosteroid receptor expression in human osterosarcoma cell lines”,J. of Endocrin., 61:455-464 (1999).
Boscaro, M., et al., “Cushing's syndrome”,The Lancet, 357:783-791 (2001).
Cooper, M.S., et al., “Expression and Functional Consequences of 11β-Hydroxysteroid Dehydrogenase Activity in Human Bone”,Bone, 27(3):375-381 (2000).
Cooper, M.S., et al., “Osteoblastic 11β-Hydroxysteroid Dehydrogenase Type 1 Activity Increases With Age and Glucocorticoid Exposure”,J. of Bone&Mineral Res., 17(6):979-986 (2002).
Davani, B., “Type 1 11β-Hydroxysteroid Dehydrogenase Mediates Glucocorticoid Activation and Insulin Release in Pancreatic Islets”,J. of Biol. Chem., 275(45:334841-34844 (2000).
de Quervain, D. J.-F., et al., “Glucocorticoid-related genetic susceptibility for Alzheimer's disease”,Hum. Molec. Genetics, 13(1):47-52 (2004).
Ilammami, M.M. & Siitteri, P.K., “Regulation of 1 1β-Hydroxysteroid Dehydrogenase Activity in Human Skin Fibroblasts: Enzymatic Modulation of Glucocorticoid Action”,J. of Clin. Endocrin&Metab., 73(2):326-334 (1991).
Hermanowski-Vosatka, A., et al., “11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice”,J. of Exp. Med., 202(4):517-527 (2005).
Hodge, G., et al., “Salt-sensitive hypertension resulting from nitric oxide synthase inhibition is associated with loss of regulation of angiotensin II in the rat”,Exp. Physiol., 87:1-8 (2002).
Issa, A.M., et al., “Hypothalamic-Pituitary-Adrenal Activity in Aged, Cognitively Impaired and Cognitively Unimpaired Rats”,J. of Neurosci., 10(10):3247-3254 (1990).
Jones, C.D., et al., “Effects of Substituent Modification on Face Selection in Reduction”,J. Org. Chem., 83(8):2758-2760 (1998).
Kolocouris, N., et al., “Synthesis an Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2”,J. Med. Chem., 39:3307-3318 (1996).
Kornel, L., et al., “Mechanism of the effects of glucocorticois and mineralocorticoids on vascular smooth muscle contractility”,Steriods, 58:580-587 (1993).
Lupien, S.J., et al., “Cortisol levels during human aging predict hippocampal atrophy and memory deficits”,Nature Neurosci., 1(1):69-73 (1998).
Mason, D., “Genetic variation in the stress response: susceptibility to experimental allergic encephalomyelitis and implications for human inflammatory disease”,Immun. Today, 12(2):57-60 (1991).
Masuzaki, H., et al., “A Transgenic Model of Fisceral Obesity and the Metabolic Syndrome”,Science, 294:2166-2170 (2001).
Masuzaki, H., et al., “Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice”,J. of Clin. Invest., 112(1):83-90 (2003).
Montague, C.T. & O'Rahilly, S., “The Perils of Portliness: Causes and Consequences of Fisceral Adiposity”,Diabetes, 49(6):883-888 (2000).
Morton, N.M., et al., “Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null Mice”,J. of Biol. Chem., 276(44):41293-41500 (2001).
Orth, D.N., “Cushing's Syndrome”,Med. Prog., 332(12):791-803 (1995).
Ortsäter, H., et al., “Regulation of 11β-hydroxyteroid dehydrogenase type 1 and glucose-stimulated insulin secretion in pancreatic islets of Langerhans”,Diabetes Metab. Res. Rev., 21:359-366 (2005).
Paterson, J.M., et al., “Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice”,Proc. Natl. Acad. Sci., 101(18):7088-7093 (2004).
Pirpiris, M., et al., Pressor responsiveness in corticosteroid-induced hypertension in humans,Hypertension, 19:567-574 (1992).
Rauz, S., et al., “Expression and Putative Role of 11β-Hydroxysteroid Dehydrogenase Isozymes within the Human Eye”,Invest. Ophthal. &Vis. Sci., 42(9):2037-2042 (2001).
Rauz, S., et al., “Inhibition of 11β-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension”,Q. J. Med., 96:481-490 (2003).
Rehman, Q. & Lane, N.E., “Effect ofGlucocorticoids on Bone Density”,Med. Pediatr. Oncol., 41:212-216 (2003).
Rook, G.A., “Glucocorticoids and immune function”,Baillier's Clin. Endocrinol. Metab., 13:576-581 (1999).
Schteingart, D.E., “Cushing Syndrome”,Princ. &Prac. Of Endoc. &Metab., Chapt. 75:723-728 (2001).
Small, G.R., et al., “Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis”,Proc. Natl. Acad. Sci., 102(34):12165-12170 (2005).
Stokes, J., et al., “Altered Peripheral Sensitivity to Glucocorticoids in Primary Open-Angle Glaucome”,Invest. Ophthalmol. Vis. Sci., 44:5163-5167 (2003).
Tronche, F., et al., “Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety”,Nature Genetics, 23:99-103 (1999).
Turner, R.T., et al., “Prednisone Inhibits Formation of Cortical Bone in Sham-Operated and Ovarictomized Female Rats”,Calcif. Tissue Int., 56:311-315 (1995).
Walker, B.R. & Williams, B.C., “Corticosteroids and vascular tone: mapping the messenger maze”,Clin. Sci., 82:597-605 (1992).
Walker, B.R., et al., “Carbenoxolone Increases Hepatic Insulin Sensitivity in Man; A Novel Role for 11-Oxosteroid Reductase in Enhancing Glucocorticoid Receptor Activation”,J. of Clin. Endocrin. &Metab., 80(11):3155-3159 (1995).
Wolkowitz, O.M., et al., “The “Steroid Dementia Syndrome” An Unrecognized Complication of Glucocorticoid Treatment”,Ann. NY Acad. Sci., 1032:191-194 (2004).
Yau, J.L.W., et al., “Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments”,Proc. Natl. Acad. Sci., 98(8):4716-4721 (2001).
Yeh, V.S.C., et al., “A Highly Efficient Synthesis of Potent and Selective Butyrolactam Inhibitors of 1 β-Hsd1”,Org. Ltrs., 8(18):3963-3966 (2006).
Kurukulasuriya Ravi
Link James T.
Madar David J.
Yeh Vince S.
Abbott Laboratories
Desai Rita J
Mabry John
Vepachedu Sreenivasarao
LandOfFree
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019252